Cardiovascular revascularization medicine : including molecular interventions
-
Cardiovasc Revasc Med · Feb 2021
Meta AnalysisSafety and Efficacy of Colchicine in Patients With Coronary Artery Disease: A Systematic Review and Meta-Analysis.
Given current evidence, the use of colchicine for the prevention of adverse cardiovascular events in patients with coronary artery disease (CAD) remains controversial. ⋯ In patients with CAD presenting with an acute coronary syndrome or stable angina, colchicine might offer no significant reduction in MACE and could potentially be harmful due to a significantly higher risk of GI-related adverse events.
-
Cardiovasc Revasc Med · Dec 2020
Mechanical circulatory support following out-of-hospital cardiac arrest: Insights from the National Cardiogenic Shock Initiative.
Evidence is limited regarding the role of mechanical circulatory support (MCS) in patients with acute coronary syndromes (ACS) complicated by cardiogenic shock (CGS). In particular, the role of MCS in patients with out-of-hospital cardiac arrest (OHCA) is unknown. ⋯ This study demonstrates that excellent outcomes may be achieved following OHCA when MCS is employed for patients appropriately selected by prognostic demographic, anatomic, and health status characteristics. A larger study population, currently being enrolled, is needed to validate the observation further.
-
Cardiovasc Revasc Med · Dec 2020
Editorial CommentKnown Knowns, Known Unknowns, and Unknown Unknowns.
-
Cardiovasc Revasc Med · Dec 2020
Meta AnalysisMeta-Analysis of the Efficacy and Safety of P2Y12 Inhibitor Monotherapy After Short Course of Dual-Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention.
Guidelines recommend dual antiplatelet therapy (DAPT) following drug-eluting stent (DES) placement for ≥12 months in acute coronary syndrome or 6 months in stable coronary artery disease. However, with the advent of newer-generation stents, the optimal duration of DAPT to balance bleeding and thrombotic risks has been debated. ⋯ A short duration of DAPT followed by P2Y12 inhibitor monotherapy was comparable to 12 months of DAPT with respect to MACE and thrombotic events, with lower rates of major bleeding events in select group of patients undergoing PCI. More data is needed to assess efficacy in patients with complex lesions and high risk ACS population including those with STEMI presentation.
-
Cardiovasc Revasc Med · Sep 2020
ReviewCost-effectiveness of transcatheter aortic valve intervention (TAVI) compared to surgical aortic valve replacement (SAVR) in low-intermediate surgical risk patients.
Transcatheter aortic valve intervention (TAVI) is known to be non-inferior to surgical aortic valve replacement (SAVR) in low-intermediate surgical risk patients. This present systematic review was conducted to analyse the cost-effectiveness of TAVI in this patient population. ⋯ TAVI is likely to be a cost-effective alternative to SAVR in low-intermediate risk patients. More studies on low risk patients is needed.